Halozyme Therapeutics (HALO) insider schedules 1,626-share stock sale via trading plan

Rhea-AI Filing Summary

Halozyme Therapeutics insider Bernadette Connaughton has filed to potentially sell 1,626 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $167,673.12 on NASDAQ as of a planned sale date of August 10, 2026. These shares relate to Restricted Stock Units granted on April 25, 2025. The filing also lists prior sales under a Rule 10b5-1 trading plan, including 1,625 shares sold on July 1, 2026 for $124,650.66 and 1,625 shares sold on June 1, 2026 for $107,591.25.

Key Figures

Planned shares to be sold: 1,626 shares Aggregate market value of planned sale: $167,673.12 Prior 10b5-1 sale on July 1, 2026: 1,625 shares for $124,650.66 +2 more

5 metrics

Planned shares to be sold 1,626 shares Common stock indicated for potential sale on August 10, 2026

Aggregate market value of planned sale $167,673.12 Value associated with 1,626 common shares to be sold

Prior 10b5-1 sale on July 1, 2026 1,625 shares for $124,650.66 Common stock sold under Rule 10b5-1 trading plan

Prior 10b5-1 sale on June 1, 2026 1,625 shares for $107,591.25 Common stock sold under Rule 10b5-1 trading plan

RSU-related shares 1,626 shares Restricted Stock Units dated April 25, 2025 underlying the planned sale

Key Terms

Form 144, Restricted Stock Units, 10b5-1, aggregate market value, +1 more

5 terms

Form 144 regulatory

"Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Units financial

"Common | 04/25/2025 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 regulatory

"10b5-1 Sales for BERNADETTE CONNAUGHTON 12390 El Camino Real"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

NASDAQ market

"113498000 | 08/10/2026 | NASDAQ 144: Securities To Be Sold"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 04:35 PM Accepted by SEC EDGAR 08/10/2026 - 04:34 PM Learn about SEC filing dates

FAQ

What stock sale is disclosed for HALO in this Form 144 filing?

The filing indicates a potential sale of 1,626 shares of Halozyme Therapeutics common stock, with an aggregate market value of $167,673.12, to be executed on NASDAQ on August 10, 2026.

Who is the insider involved in the HALO Form 144 stock sale?

The filer is Bernadette Connaughton, who has filed to potentially sell 1,626 shares of Halozyme Therapeutics common stock, with Morgan Stanley Smith Barney LLC listed as the broker handling the transaction.

What prior 10b5-1 sales of HALO stock are reported?

The filing reports prior Rule 10b5-1 sales of 1,625 shares on July 1, 2026 for $124,650.66 and 1,625 shares on June 1, 2026 for $107,591.25, both involving Halozyme Therapeutics common stock.

What type of HALO security underlies the planned Form 144 sale?

The planned sale involves Halozyme Therapeutics common stock underlying Restricted Stock Units that were granted on April 25, 2025, with 1,626 shares indicated for potential sale.

On which exchange is the HALO stock sale expected to occur?

The potential sale of 1,626 shares of Halozyme Therapeutics common stock referenced in the filing is associated with trading on the NASDAQ market, with a planned sale date of August 10, 2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1626	167673.12	113498000	08/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/25/2025	Restricted Stock Units	Issuer			1626	04/25/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for BERNADETTE CONNAUGHTON 12390 El Camino Real San Diego CA 92130	Common	07/01/2026	1625	124650.66
10b5-1 Sales for BERNADETTE CONNAUGHTON 12390 El Camino Real San Diego CA 92130	Common	06/01/2026	1625	107591.25

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)